PMID- 36466382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221206
IS  - 2296-861X (Print)
IS  - 2296-861X (Electronic)
IS  - 2296-861X (Linking)
VI  - 9
DP  - 2022
TI  - Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis 
      chronic kidney disease patients: A systematic review and meta-analysis of 
      randomized double-blind controlled clinical trials.
PG  - 1029432
LID - 10.3389/fnut.2022.1029432 [doi]
LID - 1029432
AB  - OBJECTIVE: To evaluate the efficacy and safety of roxadustat in the treatment of 
      anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. 
      MATERIALS AND METHODS: For this systematic review and meta-analysis, we searched 
      for randomized controlled trials (RCTs) of anemia in NDD-CKD patients to assess 
      the efficacy and safety of roxadustat. The primary efficacy endpoint was the 
      proportion of patients who achieved a hemoglobin (Hb) response. Secondary 
      efficacy endpoints were hepcidin, serum iron, serum ferritin (SF), total 
      iron-binding capacity (TIBC), transferrin saturation (TAST), and low-density 
      lipoprotein (LDL). In addition, adverse events (AEs) were compared. Meta-analyses 
      were performed using Revman 5.4 software. The quality of the evidence was 
      assessed using the Cochrane risk of bias tool. This study was conducted under a 
      pre-established protocol registered with PROSPERO (registration number: 
      CRD42021252331). RESULTS: Seven studies enrolled 4,764 patients, of whom 2,730 
      received roxadustat and 2,034 received placebo. The results of this meta-analysis 
      showed that roxadustat increased Hb levels [weighted mean difference (WMD) = 
      1.43, 95% CI: 1.17 to 1.68, P < 0.001, I (2) = 95%], and Hb response [relative 
      ratio (RR) = 8.12, 95% CI: 5.80 to 11.37, P < 0.001, I (2) = 61%]. In addition, 
      roxadustat significantly increased transferrin TAST. During the treatment period 
      in patients with anemia, the AEs of roxadustat compared with placebo was not 
      statistically significant. CONCLUSION: Roxadustat can improve anemia in NDD-CKD 
      patients by increasing Hb levels and regulating iron metabolism, but does not 
      increase the incidence of AEs. SYSTEMATIC REVIEW REGISTRATION: 
      [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021252331].
CI  - Copyright (c) 2022 Chen, Huang, Dong, Xu, Chen, Tang and Huang.
FAU - Chen, Ting
AU  - Chen T
AD  - The First Clinical Medical College, Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
AD  - Department of Nephrology, Gansu Provincial Hospital, Lanzhou, China.
FAU - Huang, Junyue
AU  - Huang J
AD  - Department of Nephrology, Gansu Provincial Hospital, Lanzhou, China.
FAU - Dong, Hui
AU  - Dong H
AD  - Department of Nephrology, Gansu Provincial Hospital, Lanzhou, China.
FAU - Xu, Lili
AU  - Xu L
AD  - The First Clinical Medical College, Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
AD  - Department of Nephrology, Gansu Provincial Hospital, Lanzhou, China.
FAU - Chen, Caihe
AU  - Chen C
AD  - The First Clinical Medical College, Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
AD  - Department of Nephrology, Gansu Provincial Hospital, Lanzhou, China.
FAU - Tang, Yu
AU  - Tang Y
AD  - Clinical Lab, Gansu Provincial Hospital, Lanzhou, China.
FAU - Huang, Wenhui
AU  - Huang W
AD  - Department of Nephrology, Gansu Provincial Hospital, Lanzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20221104
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC9710737
OTO - NOTNLM
OT  - anemia
OT  - chronic kidney disease
OT  - clinical trials
OT  - efficacy
OT  - hemoglobin
OT  - meta-analysis
OT  - non-dialysis
OT  - roxadustat
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2022/12/06 06:01
PMCR- 2022/01/01
CRDT- 2022/12/05 04:02
PHST- 2022/08/27 00:00 [received]
PHST- 2022/10/14 00:00 [accepted]
PHST- 2022/12/05 04:02 [entrez]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/06 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fnut.2022.1029432 [doi]
PST - epublish
SO  - Front Nutr. 2022 Nov 4;9:1029432. doi: 10.3389/fnut.2022.1029432. eCollection 
      2022.